Health Care · Surgical & Medical Instruments & Apparatus

RMD ResMed SEC Filings & Insider Trading Activity 2026

company
CIK 943819116 filings
S&P 500

RMD at a glance

ResMed (RMD, SEC CIK 943819) filed its latest 10-K annual report on August 13, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended June 30, 2026 (FY2026), ResMed (RMD) reported revenue of $5.7 billion (up 9.9% from FY2025) and net income of $1.5 billion. Diluted EPS was $10.43.
  • As of September 30, 2026, 41 institutional investment managers tracked by SignalX reported holding ResMed (RMD) shares worth $11.6 billion in 13F-HR filings.
  • In the last 90 days, RMD insiders reported 0 open-market purchases ($0) and 6 open-market sales ($3.8M) on Form 4, a net sale of $3.8M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2026
$5.7B
+9.9% vs prior year
Insiders · 90 days
0 buys · 6 sells
Net −$3.8M
13F holders
41 funds
$11.6B · +1 vs prior quarter
Latest 8-K
Nov 19, 2026
Item 5.02 · Item 5.07

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Jun 30, 2026

Full analysis →

Management Discussion & Analysis

  • Revenue $5,653M, up 10% YoY ($507M increase); Sleep and Breathing Health +10%, Residential Care Software +5%
  • Gross margin 61.1% vs 59.4%, operating margin 33.4% vs 32.7%; non-GAAP operating margin 36.1% vs 34.3%
  • Best segment: Sleep and Breathing Health revenue $4,978M (+10%); worst: Residential Care Software $676M (+5%)
  • Operating cash flow $1.8B; treasury stock repurchases $700M; dividends $350M paid; capex and acquisitions total $545M investing cash outflow
  • Management outlook implies continued growth and strategic acquisitions; risks include foreign currency effects, global minimum tax, and regulatory environment

Risk Factors

  • Direct Medicare oversight risk due to acquisitions of VirtuOx and Noctrix, subject to Anti-Kickback Statute, Stark Law, False Claims Acts, and HIPAA compliance
  • Geopolitical risk from Uyghur Forced Labor Prevention Act (effective June 2022) and Russia-Ukraine conflict potentially disrupting suppliers of raw materials
  • Supply chain risk from reliance on single-source suppliers and Chinese export controls on rare earth magnets, impacting cost and availability of components
  • Competitive risk from Philips' product recall and re-entry, plus pharmaceuticals like GLP-1 affecting market for OSA treatment devices
  • Financial risk from $660 million debt (June 30, 2026) increasing vulnerability to adverse conditions and limiting financial flexibility

Business Overview

  • Core business model: Global leader in AI-powered digital health and cloud-connected medical devices for sleep and breathing health, plus residential care software
  • New acquisition: Noctrix Health in June 2026, expanding portfolio into restless legs syndrome treatment with FDA De Novo classified wearable device
  • Strategic shift: Sold MatrixCare business for $490 million to focus on core sleep, breathing, and connected home-based healthcare growth areas
  • Employee count steady at approximately 11,370 with 31% in Americas, 31% Asia, 15% Australia, 23% Europe; 13% global turnover rate in FY 2026
  • Noteworthy development: Launched Smart Comfort feature in myAir app in early 2026, first FDA-cleared AI-enabled medical device recommending personalized therapy comfort settings

AI summary of the RMD 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to the fiscal 2026 Form 10-K risk factors as of September 30, 2026
  • Carried-forward risks include regulatory compliance, product quality, cybersecurity, competition, and market demand
  • Financial exposures remain those identified in the fiscal 2026 Form 10-K, including liquidity, debt, currency, and customer concentration risks

Management Discussion & Analysis

  • Revenue $1,415M, up $79M or 6% YoY
  • Gross margin 61.5% vs 61.2% YoY; net income $418M vs $349M
  • Best segment: Sleep and Breathing Health $1,260M, up 8%; worst: Residential Care Software $155M, down 7%
  • Cash $1.0B vs $1.5B at June 30; operating cash flow $422M vs $457M
  • $936M share repurchases and $250M debt repayment; inflationary component costs expected through fiscal 2027

AI summary of the RMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 19, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Ronald Taylor retired from the Board at the November 18, 2026 annual meeting, reducing director count from 11 to 10
  • FY2027 executive PSUs shift to three-year Adjusted EPS and Adjusted Revenue goals, replacing recent absolute and relative TSR-based design

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Stockholders re-elected all ten director nominees to serve through the 2027 annual meeting
  • PwC ratified as independent auditor for fiscal year ending June 30, 2027, with 109,994,316 votes supporting
Filed Oct 29, 2026Full analysis →

Item 8.01: Other Events

  • Quarterly cash dividend of $0.66 per share declared, signaling continued shareholder distributions
  • November 12, 2026 record date, with payment scheduled for December 17, 2026

Item EX-99.1: Item EX-99.1

  • Q1 FY2027 revenue $1.415B, up 6%, with core constant-currency growth of 7% driven by sleep devices and masks
  • GAAP diluted EPS $2.92, up 23%; non-GAAP EPS $2.91, up 14%, supported by stronger gross margin

Item 2.02: Results of Operations and Financial Condition

  • Exhibit 99.1 announces ResMed’s operating results for the quarter ended September 30, 2026
  • Investors should review the accompanying release for revenue, earnings, margins, guidance and business drivers
Filed Sep 1, 2026Full analysis →

Item 8.01: Other Events

  • $450M accelerated share repurchase announced, signaling capital return following MatrixCare business sale
  • $450M payment to Citibank scheduled September 3, 2026, funded by MatrixCare proceeds and cash on hand

AI summaries of RMD 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for RMD

Don't miss the next RMD filing

  • Alerts as it files. A push when RMD files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut RMD, by share count.
  • Ask anything. An AI agent that reads every RMD filing and answers with sources.

RMD alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
DelOrefice ChristopherANov 19, 2026-
Tan DesneyANov 19, 2026-
Burt CarolANov 19, 2026-
Leong JustinANov 19, 2026-
Drexler KarenANov 19, 2026-
Gill HarjitANov 19, 2026-
FARRELL PETER CANov 19, 2026-
De Witte JanANov 19, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2024FY2025FY2026
Profitability
Revenue-$5.1B$5.7B
Gross Profit-$3.1B$3.5B
Operating Income-$1.7B$1.9B
Net Income-$1.4B$1.5B
Gross Margin-59.4%61.1%
Op. Margin-32.7%33.4%
Net Margin-27.2%26.9%
Balance Sheet
Total Assets$6.9B$8.2B$9.0B
Equity-$6.0B$6.6B
ROE-23.5%23.1%
Per Share
EPS-$9.51$10.43
Cash Flow
Operating CF-$1.8B$1.8B
CapEx$99.5M$89.9M$156.3M

Source: XBRL data in ResMed (RMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate RMD share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
RMD shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202641$11.60B
Q2 202640$10.65B
Q1 202640$12.24B
Q4 202537$13.51B
Q3 202540$15.33B
Q2 202537$14.28B
Q1 202535$9.85B
Q4 202430$8.61B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 300 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

RMD filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 20, 2026--
8-KNov 19, 2026Analysis-
4Nov 18, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 12, 2026--
10-QOct 30, 2026Analysis
8-KOct 29, 2026Analysis-
4Oct 26, 2026--
4Oct 8, 2026--
4Oct 1, 2026--

Related Health Care companies

All Health Care →

RMD SEC filings: frequently asked questions

Are RMD insiders buying or selling?

In the last 90 days, ResMed (RMD) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $3.8 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold RMD stock?

As of September 30, 2026, the largest ResMed (RMD) holders among the 13F filers tracked by SignalX were BlackRock ($2.6 billion), Vanguard Capital Management LLC ($2.1 billion), Vanguard Portfolio Management LLC ($1.8 billion), State Street Corp ($1.4 billion), BNY Mellon ($824.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was RMD's revenue in fiscal year 2026?

For the fiscal year ended June 30, 2026 (FY2026), ResMed (RMD) reported revenue of $5.7 billion (up 9.9% from FY2025) and net income of $1.5 billion. Diluted EPS was $10.43. The figures come from the XBRL data in the 10-K.

What are the main risks in RMD's latest 10-K?

In the 10-K filed August 13, 2026, ResMed (RMD) flagged: Direct Medicare oversight risk due to acquisitions of VirtuOx and Noctrix, subject to Anti-Kickback Statute, Stark Law, False Claims Acts, and HIPAA compliance. Geopolitical risk from Uyghur Forced Labor Prevention Act (effective June 2022) and Russia-Ukraine conflict potentially disrupting suppliers of raw materials. (AI summary of the Risk Factors section.)

What did RMD report in its latest 8-K?

ResMed (RMD) filed an 8-K on November 19, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 5.07 (Submission of Matters to a Vote of Security Holders). Ronald Taylor retired from the Board at the November 18, 2026 annual meeting, reducing director count from 11 to 10.

What are the latest RMD SEC filings?

ResMed (RMD) filed its latest 10-K annual report on August 13, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on November 20, 2026.

What is RMD's SEC CIK number?

ResMed (RMD)'s SEC Central Index Key (CIK) is 943819. EDGAR lists every RMD filing under that number.

Ask anything about RMD

The research agent reads RMD's filings, financials, insider trades and 13F holders, then answers with sources.